An effective post-exposure prophylaxis (PEP) strategy may limit the spread of infection. However, there is no consensus regarding PEP for Middle East respiratory syndrome coronavirus (MERS-CoV) infection. This study assessed the efficacy of ribavirin and lopinavir/ritonavir as PEP for healthcare workers (HCWs) exposed to patients with severe MERS-CoV pre-isolation pneumonia. The safety of the PEP regimen was assessed. HCWs with high-risk exposure to MERS-CoV pre-isolation pneumonia were retrospectively enrolled. HCWs who received PEP therapy were classified into the PEP group. PEP therapy was associated with a 40% decrease in the risk of infection. There were no severe adverse events during PEP therapy.
Park, S. Y., Lee, J. S., Son, J. S., Ko, J. H., Peck, K. R., Jung, Y., … Shi, H. (2019). Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers. Journal of Hospital Infection, 101(1), 42–46. https://doi.org/10.1016/j.jhin.2018.09.005